Lecanemab-irmb 5-Year Data Show Slower Decline in Early Alzheimer Disease
Key Clinical Summary:
- Lecanemab-irmb (Leqembi) continuous treatment over 5 years in 351 Clarity AD extension participants was associated with 2.05 points less CDR-SB decline versus historic ADNI data and 2.54 points less decline versus BioFINDER data.
- Among patients with low tau in a PET substudy, 66% showed no cognitive or functional decline and 62% improved from baseline on CDR-SB after 5 years.
- Comparisons with external historic cohorts limit causal interpretation of the 5-year findings.
Continuous treatment with lecanemab-irmb (Leqembi) was associated with less cognitive and functional decline in early Alzheimer disease (AD) over 5 years compared with historic cohort groups, according to data reported at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, MA. Findings from the Clarity AD extension study also demonstrated improvements in cognitive function and activities of daily living for 62% of patients treated at earlier stages of the disease.
Clarity AD Core Trial and Long-Term Extension Design
The global, double-blind, parallel-group phase 3 Clarity AD study enrolled 1795 patients with early AD. Participants were randomized to receive either intravenous infusions of lecanemab-irmb 10 mg/kg every 2 weeks (n = 898) or placebo (n = 897).
A total of 351 patients received 5 years of continuous treatment as part of the 18-month core study and subsequent long-term extension.
Lecanemab Outcomes Compared With Historic Alzheimer Disease Cohorts
Researchers compared patient progress over 5 years of continuous treatment to historic AD data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and BioFINDER. Patients receiving continuous treatment showed 1.00 point less decline in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score after 3 years and 2.05 points less decline after 5 years compared to ADNI data. The lecanemab group also showed less decline compared to BioFINDER data, with corresponding differences of 1.42 points and 2.54 points, respectively, and increasing differences over time.
In a news release, BioArctic further reported that treatment with lecanemab-irmb also reduced the relative risk of progressing to a later stage of AD by 36% compared with ADNI data; after 5 years, 77.5% of ADNI patients had progressed to the next disease stage compared to 61.9% of patients treated with lecanemab-irmb. For those treated with lecanemab-irmb, the relative risk of progressing from early AD to moderate or severe dementia was also reduced by 49% compared with the ADNI cohort, according to the company.
In a tau PET substudy, which sought to identify patients with lower levels of tau accumulation in the brain as an indication of earlier AD stage, 66% of patients with low tau showed no decline in cognitive and functional impairment as measured by CDR-SB after 5 years of lecanemab-irmb treatment, and 62% showed improvement from baseline. The benefit was also demonstrated on other scales, including the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog14) and Alzheimer's Disease Cooperative Study – Activities of Daily Living for Mild Cognitive Impairment (ADCS MCI-ADL).
There were no new safety findings observed during the extension study. ARIA-E occurred most frequently within the first 6 months of treatment, with lower incidence in subsequent years.
Implications for Clinical Practice
The results suggest that continuous, long-term treatment with lecanemab-irmb may offer a treatment benefit in early AD. The findings from the low-tau PET subgroup also suggest an advantage of initiating treatment early in the disease course, as earlier initiation was associated with slower progression to later disease stages.
However, the 5-year analysis used external historic cohorts rather than a concurrent randomized placebo group, limiting causal interpretation of the observed differences.



